Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. DCGO
DCGO logo

DCGO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy DocGo Inc (DCGO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
0.600
1 Day change
1.36%
52 Week Range
1.780
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

DCGO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below $1 with weak longer-term trend structure, no supportive news catalyst, no strong proprietary buy signal, and no clear evidence of improving fundamentals in the data provided. My direct view: do not buy it now.

Technical Analysis

Current price is 0.5558, essentially flat versus the prior close, with only a small after-hours move. The short-term momentum is modestly positive because MACD histogram is above zero and expanding, but that is outweighed by the broader trend: SMA_200 > SMA_20 > SMA_5 is bearish and shows the stock remains in a long-term downtrend. RSI_6 at 63.06 is neutral-to-mildly bullish, not strong enough to confirm an entry. Price is sitting below resistance at 0.572 and below the next breakout area at 0.605, while pivot support is 0.519 and lower support sits at 0.466. Overall: weak technical setup, no confirmed trend reversal.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is extremely bullish on the surface, but the signal is distorted by very low activity. Call open interest is 3,484 versus put open interest of 78, producing a very low put-call ratio of 0.02. However, today’s options volume is only 5 contracts, so the reading is not robust. IV percentile is 100 and IV rank is 114, meaning options are priced with very high implied volatility. This usually favors option sellers more than stock buyers and does not strengthen the long-term equity case.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
8
Buy
4

Positive Catalysts

  • ["MACD histogram is positive and expanding, which suggests some short-term momentum improvement.", "Price is slightly above the previous close and holding near the pivot zone.", "Similar candlestick pattern data suggests a chance of near-term upside, with estimated moves of 4.59% over one week and 7.17% over one month."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst supporting a rerating.", "Bearish moving average structure indicates the longer-term trend remains weak.", "No AI Stock Picker signal today.", "No SwingMax signal recently.", "Hedge funds are neutral with no significant trading trends over the last quarter.", "Insiders are neutral with no significant trading trends over the last month.", "No recent congress trading data available.", "High implied volatility and extremely thin option volume reduce confidence in the options signal."]

Financial Performance

No usable latest-quarter financial snapshot was provided because of a data error, so there is no reliable quarter-over-quarter or year-over-year growth assessment available here. Based on the dataset alone, there is no evidence of a strong recent fundamental acceleration, and the absence of financial detail is itself a negative for a beginner long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided in the input, so there is no visible bullish revision trend to support the stock. In Wall Street terms, the pros case is weak because there is no confirmed catalyst, no strong buy signal, and no valuation support data. The cons case is stronger: bearish long-term trend, no recent news, and no clear institutional or insider accumulation.

Wall Street analysts forecast DCGO stock price to rise
4 Analyst Rating
Wall Street analysts forecast DCGO stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.588
sliders
Low
1.5
Averages
3.13
High
4
Current: 0.588
sliders
Low
1.5
Averages
3.13
High
4
Canaccord
Hold
downgrade
$1
AI Analysis
2026-03-25
Reason
Canaccord
Price Target
$1
AI Analysis
2026-03-25
downgrade
Hold
Reason
Canaccord lowered the firm's price target on DocGo to $1 from $1.50 and keeps a Hold rating on the shares. The firm updated is model following mixed Q4 results as revenue topped the high end of its guidance. DocGo has significant work left to do to scale its go-forward Mobile Health business and rightsize its cost structure to regain adj-EBITDA profitability targeted in 2H 2026. The formal process exploring strategic alternatives may deliver a positive outcome for shareholders, but fundamentally, Canaccord maintains its "show me" stance.
Stifel
Buy
maintain
$4
2026-03-17
Reason
Stifel
Price Target
$4
2026-03-17
maintain
Buy
Reason
Stifel lowered the firm's price target on DocGo to $2.50 from $4 and keeps a Buy rating on the shares. Q4 results were mixed and 2026 guidance was raised modestly to reflect improving growth in its transport segment, notes the analyst, who estimates transportation could potentially generate $15M-$20M of 2026 EBITDA pre-overhead and contends that this "implies this unit alone could yield proceeds above current share-price."
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for DCGO
Unlock Now

People Also Watch